Featuring a roundtable discussion with Dr Elizabeth R Plimack,
Dr Jonathan E Rosenberg, Mr Andrew Ruplin and Ms Cristina Salabao
on the following topics:
First-Line Systemic Therapy for Patients with Metastatic UBC
(mUBC)
Overview of interdisciplinary care in UBC (0:00)
Counseling patients with newly diagnosed mUBC about prognosis
and treatment options (3:50)
Recent advances in the management of mUBC (12:01)
Mechanism of action, efficacy and side effects of immune
checkpoint inhibitors (18:50)
Design, results and clinical implications of the Phase III
JAVELIN Bladder 100 trial evaluating first-line maintenance therapy
with avelumab and best supportive care (BSC) versus BSC alone for
patients with mUBC who had not experienced disease progression
after induction chemotherapy (25:51)
Selection of first-line therapy for patients with mUBC
(29:03)
Choice of up-front therapy for older patients with mUBC; role
of PD-L1 expression in selection of therapy (36:57)
Enfortumab Vedotin for Patients with Advanced UBC
Mechanism of action, activity and tolerability of enfortumab
vedotin for advanced UBC (45:27)
Dose and schedule of administration of enfortumab vedotin;
associated peripheral neuropathy, hyperglycemia and ocular
toxicities (50:49)
Case: A woman in her early 70s with mUBC and a history of
multiple sclerosis receives enfortumab vedotin after disease
progression on neratinib/paclitaxel — Cristina Salabao, MSN, FNP-C
(1:02:30)
Case: A woman in her late 60s with mUBC receives enfortumab
vedotin after disease progression on sacituzumab govitecan — Andrew
Ruplin, PharmD (1:10:12)
Case: A man in his early 80s receives enfortumab vedotin for
mUBC — Elizabeth R Plimack, MD, MS (1:14:53)
Case: A man in his late 80s attains a stable response with
enfortumab vedotin for mUBC — Jonathan E Rosenberg, MD
(1:20:56)
Role of Erdafitinib in the Treatment of Advanced UBC
Biologic rationale for, efficacy of and pharmaceutical
considerations with erdafitinib for patients with mUBC and FGFR
gene alterations (1:24:14)
Monitoring and management of ocular, skin and nail toxicities
and hyperphosphatemia associated with erdafitinib (1:30:13)
Case: A woman in her early 70s develops rash, mucositis and
nail changes after treatment with erdafitinib for mUBC with an
FGFR3 alteration — Dr Rosenberg (1:37:50)
Case: A woman in her mid-70s with mUBC and an FGFR3 alteration
receives erdafitinib after disease progression on
cabozantinib/atezolizumab — Ms Salabao (1:39:15)
Case: A man in his early 60s develops hyperphosphatemia and
central serous retinopathy after therapy with erdafitinib for mUBC
with an FGFR alteration — Dr Ruplin (1:42:02)
Case: A man in his late 70s with mUBC with an FGFR3 alteration
attains a good response to erdafitinib — Dr Plimack (1:47:32)
Novel Agents and Approaches for Patients with mUBC
Biologic rationale for the combination of enfortumab vedotin
and pembrolizumab; efficacy in the first-line setting for patients
with advanced UBC (1:53:35)
Emerging data with the antibody-drug conjugates sacituzumab
govitecan and trastuzumab deruxtecan for mUBC (1:59:02)
Management of mUBC in the COVID-19 Era
Approach to therapy for patients with mUBC during the COVID-19
pandemic; role of telemedicine in patient care (2:06:08)
Impact of COVID-19 on clinical research and the care of
patients with UBC (2:13:50)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.